Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders

A cannabinoid, cannabis technology, applied in the treatment and prevention of chronic and acute inflammatory diseases in mammals, the field of pharmaceutical compositions containing this complex mixture, can address the safety, efficacy and consistency of plant-derived medicines that have not approached the To reduce the ethical burden and reduce the regulatory burden

Pending Publication Date: 2019-12-03
GBS GLOBAL BIOPHARMA INC
View PDF13 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, the safety, efficacy, and consistency of plant-derived medicines have not y...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
  • Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
  • Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0228] 5.9.1. Example 1: Submixtures Containing Minor Cannabinoids and / or Terpenes (ENT 1-ENT12A)

[0229]Twenty-one different subblends (ENT 1-ENT 12A) containing minor cannabinoids and / or terpenes were generated by mixing the individual components specified in Table 1. Components were obtained from various suppliers - nerolidol (#N0454) from Tokyo Chemical Industry, linalool (#L0048) from Tokyo Chemical Industry, a-pinene (#P45680) from Sigma Aldrich, from MP Limonene (#155234) from Biomedicals, Phytol (#FLMS-035) from Ultr Scientific, Cannabidiol (#C-140) from Sigma Aldrich, Cannabichromene (#C-143) from Sigma Aldrich , Cannabidiol (#C-045) from Sigma Aldrich, Cannabigerol (#C-141) from Sigma Aldrich and Cannabidiol (#C-046) from Sigma Aldrich. Each component is added in such an amount that each submixture contains the same molar concentration of each individual component.

[0230] Similarly, a cannabinoid-containing complex mixture was created by mixing the main cannabin...

Embodiment 2

[0231] 5.9.2. Example 2: Anti-inflammatory effect of cannabinoid-containing complex mixtures measured based on the inhibition of histamine release

[0232] The anti-inflammatory effects of various cannabinoid-containing complex mixtures comprising cannabidiol and one of twelve sub-blends (ENT1-12) were tested by an FcεRI linkage-based in vitro assay.

[0233] FcεRI is a high-affinity receptor for the Fc region of immunoglobulin E (IgE), an antibody isotype involved in allergy and parasite immunity. FcεRI is multimeric and a member of a family of related antigen / Fc receptors that share conserved structural features and similar roles in initiating intracellular signaling cascades. In humans, FcεRI controls the activation of mast cells and basophils and is involved in IgE-mediated antigen presentation. Multivalent antigens bind through FcεRI and cross-link IgE molecules held on the cell surface. Receptor aggregation induces multiple signaling pathways that control different eff...

Embodiment 6

[0262] 5.9.6. Example 6: Cellular and molecular mechanisms of anti-inflammatory effects of complex mixtures containing cannabinoids

[0263] Cannabigerol (CBG) can have anti-inflammatory effects by (1) inhibiting secretory pathways or (2) stimulating antisecretory pathways or both, i.e. inhibiting degranulation. Activation of the Gi-coupled receptors CB1 and CB2 induces Gi-mediated inhibition of adenylyl cyclase and subsequent reduction in intracellular cAMP concentration. Since CBG is an antagonist against CB1 and CB2, both expressed on RBL mast cells, inhibition of CB1 and CB2 by CBG can increase intracellular cAMP and inhibit mast cell degranulation. Increased cAMP is known to inhibit degranulation of mast cells.

[0264] CB1 and CB2 receptors can be constitutively activated by their endogenous ligands such as anandamide (arachidonyl ethanolamine or AEA). AEA is metabolized by fatty acid amide hydrolase (FAAH), therefore, inhibition of FAAH can increase endogenous AEA lev...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol,a first minor cannabinoid, which is cannabigerol, at least a first selected terpene, and optionally a second minor cannabinoid. Also provided are methods of making the complex mixtures, pharmaceuticalcompositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of mast cell-related immune disorders, including allergy and atopy (allergic asthma, eczema, rhinitis), mast cell activation syndrome (MCAS), physical and chemical urticarias, idiopathic urticaria, Crohn's disease, inflammatory bowel disorder, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, canine mastocytosis, and allergy and inflammation in cattle, swine, etc. The methods of the present invention further relate to the treatment of various basophil-mediated immune disorders.

Description

[0001] 1. Cross references to related applications [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 453,161, filed February 1, 2017, which is hereby incorporated by reference in its entirety. [0003] 2. Background technology [0004] Inflammatory responses can be beneficial physiologically and pathophysiologically, as inflammatory responses are necessary for wound healing, resolution and recovery of viral or bacterial infections. However, excessive inflammatory responses are detrimental as they involve anaphylaxis or anaphylactoid reactions, allergic or idiopathic inflammation. Mast cells are central to the initiation and maintenance of inflammation. [0005] Mast cells are strategically located in the body: they are close to blood vessels, nerves and lymphatic vessels in tissues in contact with the external environment (eg, airway, gastrointestinal tract, uterus, skin). In response to various stimuli (including challenges to innate and ad...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/015A61K31/045A61K31/05A61K31/352A61P17/04A61P37/08A61P37/00A61P17/00A61P19/02A61P41/00
CPCA61K31/045A61K31/352A61P17/04A61P37/08A61P41/00A61P17/00A61P19/02A61K31/05A61K31/355A61P37/00A61K31/015A61K2300/00A61K36/185
Inventor A·斯马尔-霍华德H·特纳
Owner GBS GLOBAL BIOPHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap